Introduction
============

With the development of sequencing and bioinformatics technologies, accumulating studies have revealed that different patients may be similar in glioma grade but differ greatly in molecular characteristics, clinical prognosis and treatment response. So many central nervous system tumors were named according to molecular parameters and histopathologic diagnosis, especially gliomas, ependymomas and medulloblastomas in the 2016 revision of the WHO classification ([@ref-32]). As we know, some molecular markers, such as MGMT (O6-methylguanine DNA methyltransferase) ([@ref-3]), isocitrate dehydrogenase (IDH) ([@ref-14]), epidermal growth factor receptor (EGFR) ([@ref-7]) and phosphatase and tensin homolog (PTEN) ([@ref-13]) that have contributed to personalized therapeutic approaches and targeted anti-glioblastoma therapies have been routinely tested in glioblastoma patients clinically ([@ref-28]). However, there are few specific clinical indicators and therapeutic targets for LGGs compared to glioblastoma, so there is an urgent need to elucidate the mechanism of glioma development and progression, which can provide potential treatment targets for LGGs.

In this study, gene expression RNAseq data and corresponding clinical information of LGG patients were downloaded from UCSC Xena (<https://xenabrowser.net/hub/>) and Chinese Glioma Genome Atlas (CGGA, <http://www.cgga.org.cn/>). By analyzing data from UCSC Xena using a robust likelihood-based survival model and Cox regression, we developed a three-gene signature that provides effective survival risk stratification of patients with LGG and validated the signature in the CGGA dataset. These results demonstrate the potential of the three-gene signature for survival prediction of patients with LGG and provide new potential molecular treatment targets for LGGs.

Materials and Methods
=====================

Dataset of patients with LGG
----------------------------

The LGGs RNA sequencing (RNAseq) data and corresponding clinical information were downloaded from The Cancer Genome Atlas (TCGA) hub by the University of California, Santa Cruz, Xena browser (<https://xenabrowser.net/hub/>) and CGGA data portal (<http://www.cgga.org.cn/>) respectively. The TCGA RNAseq data (level 3) shows the gene-level transcription estimates, as in log2(*x* + 1) transformed RSEM normalized count. The CGGA data displays the gene expression level as fragments per kilobase transcriptome per million fragments (FPKM), which has been standardized. Expressed gene defined only if its expressed level is larger than zero at half of samples. Only patients with a clear information of survival and detailed history of radiotherapy and chemotherapy/molecular therapy were included in the study. Finally, 456 cases from TCGA dataset and 159 cases from the CGGA dataset were included in the training set and validation set respectively. [Table 1](#table-1){ref-type="table"} summarized the clinical characteristics and therapy information of the training set and validation set. The workflow presentation of this study is shown in [Fig. 1](#fig-1){ref-type="fig"}.
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###### Clinical parameters of patients in the training set and validation set.
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  Variables                       Training set (*n* = 456)   Validation set (*n* = 159)   *p-*value
  ------------------------------- -------------------------- ---------------------------- -----------
  **Age group (Median)**                                                                  0.5448
  Younger                         232                        86                           
  Old                             224                        73                           
  **Sex**                                                                                 0.1894
  Female                          210                        63                           
  Male                            246                        96                           
  **Grade**                                                                               0.09385
  G2                              221                        90                           
  G3                              235                        69                           
  **Molecular therapy**                                                                   
  Yes                             263                        /                            
  NO                              193                        /                            
  **Chemoterapy**                                                                         
  Yes                             /                          80                           
  NO                              /                          79                           
  **Risk level**                                                                          1
  High                            228                        79                           
  Low                             228                        80                           
  **IDH_status**                                                                          
  Wildtype                        /                          43                           
  Mutant                          /                          116                          
  **1p19q_status**                                                                        
  Non_codel                       /                          52                           
  Codel                           /                          107                          
  **Radiation therapy**                                                                   3.52E−10
  Yes                             280                        141                          
  NO                              176                        18                           
  **Age (years)**                                                                         
  Mean ± SD                       43.4 ± 13.3                40.7 ± 10.9                  0.989
  Median                          41                         40                           
  **Vital status**                                                                        
  Alive                           341                        77                           
  Dead                            115                        82                           
  **Survival time (days)**                                                                
  Mean                            998.6 ± 953.8              2,024.7 ± 1334.3             5.27E−24
  Median                          714.5                      2,340                        
  **Histologic type**                                                                     
  Astrocytoma                     162                        34                           
  Oligodendroglioma               171                        21                           
  Oligoastrocytoma                123                        35                           
  Anaplastic astrocytomas         /                          26                           
  Anaplastic oligoastrocytomas    /                          32                           
  Anaplastic oligodendrogliomas   /                          11                           

![Study outline.\
The outline indicates the exploration process.](peerj-08-8312-g001){#fig-1}

Identification of survival-related genes and construction of the prognostic model
---------------------------------------------------------------------------------

By using the rbsurv package in R, a robust likelihood-based survival model was conducted to identify survival-related genes ([@ref-8]). The rbsurv package is a software program, which selects survival-associated genes based on the partial likelihood of the Cox model and adopts a cross-validation approach for robustness. According to the description of the rbsurv package, prior gene selection such as univariate survival modeling can be performed if necessary and the univariate survival modeling can be performed in this software program. Compared to the survival modeling without an adjustment of risk factors, the robust likelihood-based survival model can improve the ability to discover truly survival-associated genes by modeling genes after adjusting for certain risk factor. Thus, we directly conduct a robust likelihood-based survival model to screen for the prognostic genes. The robustness test was performed on 20,530 genes and 456 samples. After 10 iterations, 29 prognostic related genes were selected. With the help of glmnet and survival package in R, least absolute shrinkage and selection operator (LASSO) regression and the multivariable Cox proportional hazard regression method were used to further identify the survival-related prognostic model. The same approach was used to identify gene signatures for endometrial carcinoma ([@ref-19]). At last, three prognostic survival-related genes that were independent survival predictors and their regression coefficients were obtained at a threshold of *p* \< 0.05. Based on the median expression value of each survival-related gene, we dichotomized 456 LGGs patients into low and high expression groups and compare the survival rate between the two groups by Kaplan--Meier plots and Log-rank test. According to the estimated regression coefficients, a prognostic risk score for each patients was then calculated ([@ref-24]). The risk score = (0.4470 × expression level of WEE1) + (−0.1530 × expression level of CRTAC1) + (−0.3723 × expression level of SEMA4G). With the three-gene signature, 456 LGGs patients were divided into high-risk and low-risk groups with the median risk score as the cut-off value. Kaplan--Meier curves were performed to estimate and compare the survival for TCGA LGGs patients with a high score or a low score. The receiver operating characteristic (ROC) curve and area under the curve (AUC) were applied to evaluate the prediction accuracy of the risk score model. Furthermore stratified survival analysis was performed in patients with different age group (younger, old), gender (male, female) and pathologic grade (G2, G3).

Univariate and multivariate Cox hazard regression analysis were conducted for the potential prognostic factors such as age group (younger vs. old), gender (male vs. female), pathologic grade (G2 vs. G3), radiation therapy (Yes vs. No), molecular therapy (Yes vs. No) and risk score (High vs. Low).

Validation of the prognostic model in the CGGA
----------------------------------------------

The prognostic model was validated in the CGGA mRNAseq_325 cohort. Only patients with a clear information of survival, detailed history of radiotherapy and chemotherapy were included in the study. Finally, 159 cases from the CGGA mRNAseq_325 cohort were included in the validation set.

Exploring co-expression genes by WGCNA
--------------------------------------

To explore the regulatory network of the three genes, Gene Co-expression Network Analysis (WGCNA) was performed in training set by the R package WGCNA ([@ref-15]). The top 50% variance of genes were selected for WGCNA. In other words, WGCNA based on 456 samples and 10,256 genes. First, RNAseq data were filtered to reduce outliers. Using the absolute value of the correlation between the expression levels of transcripts, a co-expression similarity matrix was constructed. Then, the co-expression similarity matrix was transformed to the adjacency matrix by choosing nine as a soft threshold. Co-expression gene module was established by the topological overlap measure. In order to identify the significance of each module, gene significance (GS) was calculated to estimate the correlation between genes and sample traits. Module significance (MS) was defined as the average GS within modules and was calculated to measure the correlation between modules and sample traits (vital status). Finally, the "vital status" related modules that contain the three genes as members and genes belong to such modules were identified. Genes interacted with those three genes were screened and the co-expression network was constructed by Cytoscape software ([@ref-23]).

Functional enrichment analysis
------------------------------

Using Enrichment analysis of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway were conducted via the clusterProfiler package in R language ([@ref-29]) for those genes that belong to the "vital status" related modules associated with the three genes. Benjamini--Hochberg (BH)-adjusted *p*-value \< 0.05 were considered significant.

Results
=======

Three prognostic genes were identified in TCGA dataset and validated in CGGA dataset
------------------------------------------------------------------------------------

A total of 456 patients and 20,530 genes were included in the TCGA-LGG to train the prognostic model. The robust likelihood-based survival model found 29 survival-related genes, 13 genes were obtained through LASSO Cox method ([Fig. 2](#fig-2){ref-type="fig"}). We further reduced the dimensionality of these high-dimensional data by multivariate Cox proportional hazard regression model. Finally, three genes that were independent survival predictors were identified as survival prediction signature. Those three genes included in the model were WEE1, SEMA4G, CRTAC1. It has been reported that WEE1 is closely related to the growth, invasion and migration of glioma ([@ref-26]). Currently, there is no study revealing the role of SEMA4G and CRTAC1 in gliomas. After calculating the risk score, patients were divided into a high- and low-risk group based on the median cut-off point of the risk score. The three-gene signature risk score distribution is shown in [Fig. 3A](#fig-3){ref-type="fig"}. Besides, the relationship between risk score and the status of the LGGs was calculated ([Fig. 3B](#fig-3){ref-type="fig"}). As shown in the heat map of the [Fig. 3C](#fig-3){ref-type="fig"}, a remarkable high expression was noted for WEE1 in the high-risk group, while a lower expression was observed for the other genes in the high-risk group ([Fig. 3C](#fig-3){ref-type="fig"}). Patients in the high-risk group were significantly worse off the overall survival time compared to the low-risk group (*p* \< 0.0001) ([Fig. 4A](#fig-4){ref-type="fig"}). The area under ROC curve of the signature for 1-, 3- and 5-year overall survival was 0.908, 0.878 and 0.827, respectively, in training set. ([Fig. 4B](#fig-4){ref-type="fig"}). A similar result can be noted in the validation dataset ([Fig. 4C](#fig-4){ref-type="fig"}). The area under ROC curve of the signature for 1-, 3- and 5-year overall survival was 0.781, 0.806 and 0.807, respectively, in validation set. ([Fig. 4D](#fig-4){ref-type="fig"}). Moreover, the predicting power of the risk score model was not decreased in subgroup analysis for age group (younger, *p* = 0.00012; old, *p* \< 0.0001), gender (male, *p* \< 0.0001; female, *p* \< 0.0001), and pathologic grade (G2, *p* = 0.00013; G3, *p* \< 0.0001) in the training set ([Figs. 5A](#fig-5){ref-type="fig"}--[5F](#fig-5){ref-type="fig"}). The same trend can be observed in the validation dataset ([Figs. 6A](#fig-6){ref-type="fig"}--[6F](#fig-6){ref-type="fig"}). For the WEE1, the member of high expression group had significantly shorter survival than those in low expression group (*p* \< 0.0001) ([Fig. 7A](#fig-6){ref-type="fig"}). For the SEMA4G and CRTAC1, the member of high expression group had significantly longer survival than those in low expression group (*p* \< 0.0001) ([Figs. 7B](#fig-7){ref-type="fig"} and [7C](#fig-7){ref-type="fig"}). The expression level of WEE1 was significantly higher in grade III compared to grade II (*p* \< 0.0001), while the other are opposite ([Fig. 8A](#fig-8){ref-type="fig"}). These results can also be verified in the validation dataset ([Figs. 7D](#fig-7){ref-type="fig"}--[7F](#fig-7){ref-type="fig"} and [8B](#fig-8){ref-type="fig"}).

![The LASSO regression used to reduce the dimensionality of survival related genes.](peerj-08-8312-g002){#fig-2}

![Risk score analysis, survival status and survival time between two risk group and expression distribution of the three-gene signature in TCGA dataset.\
(A) The three-gene signature risk score distribution. (B) Scatterplot of patient survival status ordered by risk score. (C) The heat-map of the three-gene expression profiles after standardized and centralized.](peerj-08-8312-g003){#fig-3}

![Establishment and verification of the risk model in the training set and validation set.\
(A) Patient in high-risk group displayed significantly shorter survival time compared to those in low-risk group in training set (*p* \< 0.0001). (B) The ROC for predicting the 1-, 3- and 5-year survival and AUC for the risk score model showed good accuracy in training set, the area under the ROC curve were 0.908 (95% confidence interval (CI) \[0.858--0.958\]), 0.878 (95%CI \[0.840--0.950\]) and 0.827 (95%CI \[0.753--0.902\]). (C, D) The same result can be observed in the validation set, and the area under the ROC curve were 0.781 (95%CI \[0.684--0.877\]), 0.806 (95%CI \[0.726--0.886\]) and 0.807 (95%CI \[0.732--0.881\]) for 1-, 3- and 5-year survival.](peerj-08-8312-g004){#fig-4}

![Stratified survival analysis based on the risk model in the training set.\
Based on the risk score model, stratified survival analysis performed in patients with different age group (A and D), gender (B and E), and pathologic grade (C and F) in the training set.](peerj-08-8312-g005){#fig-5}

![Stratified survival analysis based on the risk model in the validation set.\
Based on the risk score model, stratified survival analysis performed in patients with different age group (A and D), gender (B and E), and pathologic grade (C and F) in the validation set.](peerj-08-8312-g006){#fig-6}

![The expression level of the three genes can divided the patients into different prognostic group in both training set and validation set.\
For the WEE1, the member of high expression group had significantly shorter survival than those in low expression group (*p* \< 0.0001) (A and D). For the CRTAC1, the member of high expression group had significantly longer survival than those in low expression group (*p* \< 0.0001) (B and E). For the SEMA4G, the member of high expression group had significantly longer survival than those in low expression group (*p* \< 0.0001) (C and F).](peerj-08-8312-g007){#fig-7}

![Expression of the three genes between grade II tumor and grade III tumor in training set and validation set.\
In the training set, the expression level of WEE1 was significantly higher in grade III compared to grade II (*p* \< 0.0001), while the other are opposite (A). These results can also be verified in the validation dataset (B).](peerj-08-8312-g008){#fig-8}

Multivariate Cox proportional hazard regression demonstrated that age group (HR = 0.274, *p* = 2.21E−09), pathologic grade (HR = 2.49, *p* = 0.00011) and risk score (HR = 0.198, *p* \< 0.000000000168) were independent prognostic factors in the training set, while pathologic grade (HR = 3.799, *p* = 0.00000151), 1p19q status (HR = 4.566, *p* = 0.0000388), radiation therapy (HR = 0.524, *p* = 0.046), and risk score (HR = 0.415, *p* = 0.000653) were independent prognostic factors in validation dataset ([Table 2](#table-2){ref-type="table"}).
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###### Univariate and multivariate Cox regression analyses of the risk score and other clinicopathological factors in training set and validation set.

HR, Hazard ratio; 95%CI, 95% confidence interval.
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  Variables                                  Training set (*n* = 456)   Validation set (*n* = 159)                                                                                                        
  -------------------- --------------------- -------------------------- ---------------------------- --------- ------- -------------- ---------- ------- --------------- --------- ------- -------------- ------------
  Age group (Median)   Younger vs. old       0.278                      0.184--0.420                 1.3E−09   0.274   0.179--0.418   2.21E−09   0.817   0.530--1.261    0.363     1.051   0.654--1.691   0.837
  Sex                  Male vs. Female       1.043                      0.721--1.509                 0.823     1.081   0.743--1.572   0.686      0.641   0.416--0.989    0.044     0.651   0.412--1.028   0.066
  Grade                G3 vs. G2             3.301                      2.196--4.963                 9.3E−09   2.49    1.568--3.953   0.00011    3.590   2.292--5.625    2.4E−08   3.799   2.205--6.545   0.00000151
  Molecular therapy    Yes vs. No            1.366                      0.924--2.018                 0.117     0.893   0.578--1.379   0.608      /       /               /         /       /              /
  Chemoterapy          Yes vs. No            /                          /                            /         /       /              /          2.216   1.409--3.485    0.00057   1.041   0.614--1.765   0.881
  Risk level           Low vs. High          0.188                      0.118--0.299                 2.1E−12   0.198   0.120--0.325   1.68E−10   0.246   0.153--0.394    5.7E−09   0.415   0.251--0.688   0.000653
  IDH_status           Wildtype vs. Mutant   /                          /                            /         /       /              /          2.496   1.582--3.937    8.4E−05   0.995   0.600--1.650   0.983
  1p19q_status         Non_codel vs. Codel   /                          /                            /         /       /              /          6.554   3.358--12.790   3.6E−08   4.566   2.215--9.414   0.0000388
  Radiation therapy    Yes vs. No            1.996                      1.278--3.118                 0.00236   0.814   0.488--1.358   0.43       0.475   0.262--0.861    0.0141    0.524   0.277--0.990   0.046

Calculation of module-trait correlation in LGGs and module visualization of the network connections
---------------------------------------------------------------------------------------------------

Using the R package WGCNA, gene modules were identified based on the top 50% variance of genes. To analyze the relationship between gene modules and sample clinical information, we used the module eigengene (ME) as the overall gene expression level of the corresponding modules and calculated correlations with clinical phenotypes, for example, vital status. We obtained 16 gene modules ([Figs. S1A](#supp-4){ref-type="supplementary-material"}--[S1D](#supp-4){ref-type="supplementary-material"}) with size ranging from 31 to 1,501 genes. We assigned each co-expression module an arbitrary color for reference: black, blue, brown, cyan, green, greenyellow, lightcyan, magenta, midnightblue, pink, purple, red, salmon, tan, turquoise and yellow. These modules contained 449, 1,352, 850, 46, 519, 91, 31, 201, 43, 336, 135, 462, 51, 90, 1,501 and 845 genes, respectively. As a single group, the non-co-expressed group designated as "grey" based on the WGCNA developer's rationale. Vital status related modules, such as yellow, green, black modules that contain the three genes as members and genes belong to such modules were screened ([Fig. S1D](#supp-4){ref-type="supplementary-material"}). Finally, 32 genes were discovered to be co-expressed with CRTAC1, 181 genes were co-expressed with WEE1, six genes with SEMA4G. We exported the screened genes and three prognostic survival-related genes into Cytoscape and constructed the co-expression network ([Fig. 9](#fig-9){ref-type="fig"}).

![Co-expression network of the three-gene signature.\
The co-expression networks of WEE1 (A), CRTAC1 (B) and SEMA4G (C) are shown. Yellow nodes show key genes and blue nodes are genes which co-expressed with the key genes.](peerj-08-8312-g009){#fig-9}

GO and KEGG analysis of screened genes interacted with three-gene signature
---------------------------------------------------------------------------

For the "biological processes" (BP), chromosome segregation, nuclear division, mitotic nuclear division, organelle fission, mitotic sister chromatid segregation were the commonly enriched categories ([Fig. 10A](#fig-10){ref-type="fig"}). For the "cellular component" (CC), the enriched categories were correlated with condensed chromosome, chromosome/centromeric region, chromosomal region, kinetochore, condensed chromosome/centromeric region ([Fig. 10B](#fig-10){ref-type="fig"}). For the "molecular function" (MF), these screened genes mainly enriched in microtubule binding, tubulin binding, histone kinase activity, DNA-dependent ATPase activity, protein serine/threonine kinase activity ([Fig. 10D](#fig-10){ref-type="fig"}). KEGG pathway enrichment analysis suggested that cell cycle was the most important pathway for these selected genes. The following pathway also involved many screened genes, including, oocyte meiosis, progesterone-mediated oocyte maturation, fanconi anemia pathway, homologous recombination ([Fig. 10C](#fig-10){ref-type="fig"}). Additionally, For the GO analysis, these three co-expression gene modules (yellow, green, black) enriched results can been seen in [Figs. S2](#supp-5){ref-type="supplementary-material"} and [S3](#supp-6){ref-type="supplementary-material"}.

![The most significantly enriched GO annotations and KEGG pathways of co-expressed genes. The length of the bars and the size of the dots represents the numbers of genes, and the color of the bars/dots corresponds to the *p*-value according to legend.\
(A) Top 5 significantly enriched biological process. (B) Top 5 significantly enriched cellular component. (C) Top 5 significantly enriched KEGG pathways. (D) Top 5 significantly enriched molecular function.](peerj-08-8312-g010){#fig-10}

A comparison between our and other models
-----------------------------------------

Recently, [@ref-30] reported a model containing three genes (EMP3, GSX2, EMILIN3) based on integrative analysis of DNA methylation and gene expression in TCGA dataset. [@ref-31] also reported a 4-gene (EMP3, GNG12, KIF2C, IFI44) prognostic signature based on genes encodes by chr1p/19q. To compare the prognostic values of our prognostic signature and their model, we performed time-dependent ROC curve analysis in our model and other models based on the risk score calculated by the regression coefficients which obtained by themselves and the expression level of members in their signature were shown in both TCGA and CGGA dataset. The results exhibited that our model displayed a satisfactory predictive value in predicting 1-, 3- and 5-year overall survival compared to other models ([Figs. 11A](#fig-11){ref-type="fig"}--[11F](#fig-11){ref-type="fig"}). In other words, our 3-gene model had a satisfactory efficiency in predicting both short- and long-term prognosis.

![Comparison of our 3-gene model and other literature models.\
The-dependent ROC analysis was performed to compare the three models in predicting 1-year, 3-year, and 5-year overall survival in TCGA dataset (A--C) and CGGA dataset (D--F).](peerj-08-8312-g011){#fig-11}

Discussion
==========

From the perspective of traditional pathology, the diagnosis of low-grade glioma depends on pathological type and pathological grade. With the development of sequencing technology, molecular biomarkers for the diagnosis of LGG have attracted widespread attention ([@ref-5]). Prognostic factors for the low-grade glioma that are well known include IDH mutations ([@ref-2]; [@ref-27]), 1p/19q co-deficiency ([@ref-31]), ATRX mutation ([@ref-20]), TERT promoter mutations ([@ref-6]), CIC loss ([@ref-22]), FUBP1 loss ([@ref-22]) and PTEN loss ([@ref-21]) and the above prognostic marker contribute to clinicians to understand the mechanism of low-grade gliomas. The complex pathogenesis of LGG encourages us to explore more prognostic markers for further understand it and develop an efficient treatment.

In this study, we identified three genes that were closely correlated with LGG prognosis. Considering the differentially expressed genes (DEGs) between tumor and normal tissue might not be associated with survival ([@ref-16]) and the univariate survival modeling can be performed in rbsurv package, the robust likelihood-based survival model was performed using the rbsurv package in R as the first step instead of screening for DEGs and conducting the univariate Cox regression. LASSO and Cox proportional hazard regression model are widely used to generate prognostic genes in the context of high dimensional data, thus were adopted in subsequent analysis. Compared to a single predictive biomarker, integrating multiple biomarkers into a signature is believed to be more predictive. The risk score calculated by the risk model was considered to have good predictive capabilities and was demonstrated to be an independent prognostic factor after adjusting the effects of age, sex, tumor grade, molecular therapy and radiation therapy. The risk score was confirmed to be effective in different age groups, gender and pathologic grade. Regardless of the training set or the validation set, the AUC value of 1-, 3- and 5-year was greater than 0.75. The pathologic grade and the risk level were confirmed to be independent prognostic factors both in training set and validation set.

In order to construct a co-expression network of the three genes, WGCNA was used in the training set. We found the survival related modules to which these three genes belong, and extracted the genes of these three modules to construct a co-expression network. Finally, 32 genes were discovered to be co-expressed with CRTAC1, 181 genes were co-expressed with WEE1, six genes with SEMA4G. The co-expression network of the three genes is visualized by Cytoscape in [Fig. 9](#fig-9){ref-type="fig"}.

Based on the result of GO and KEGG enrichment analysis of these co-expression genes, "condensed chromosome" was the most significant enrichment in CC. Coincidentally, Rebecca et al. found that interference with chromatin condensation results in failure to fully activate DNA damage response ([@ref-4]) and the DNA damage response triggers multiple cellular events including activation of DNA repair pathway, arrest of the cell cycle to allow time for repair, and, in certain cases, initiation of senescence or apoptosis programs ([@ref-9]). For the BP category, chromosome segregation was the most enrichment and research has proven that chromosome instability contributes to the development of genetic heterogeneity in tumors and allows the outgrowth of tumorigenic cells with advantageous karyotypes ([@ref-10]). Regarding the MF category, microtubule binding was the most influential and the drug targeted microtubule was proven effective in glioma. For example, the drug EM011 functions by disrupting microtubule dynamics and modules several oncogenic mediators causing a decrease in cell viability, proliferation and migration/invasion in the astrocytoma cell lines ([@ref-1]). For KEGG pathway enrichment analysis, cell cycle was the most significant pathway. Stephen D has explained that signaling pathway converge on the cell cycle machinery to regulate developmental genes and execute cell fate decisions ([@ref-11]).

The three-gene signature provided a wealth of potential biological and therapeutic information about LGG.WEE1 (WEE1 G2 checkpoint kinase), located on the short arm of human chromosome 11 (11p15.4), encodes a nuclear protein, which is a tyrosine kinase belonging to the Ser/Thr family of protein kinases. The protein catalyzes the inhibitory tyrosine phosphorylation of CDC2/cyclin B kinase, and appears to coordinate the transition between DNA replication and mitosis by protecting the nucleus from cytoplasmically activated CDC2 kinase. WEE1 has been confirmed that its protein expression increases with malignancy grade ([@ref-18]). Moreover, patients with high WEE1 expression had poor survival than did patients with low WEE1 expression in grade III gliomas ([@ref-18]). CRTAC1, cartilage acidic protein 1, a novel human marker which allowed discrimination of human chondrocytes from osteoblasts and mesenchymal stem cells in culture can be divided into CRTAC1-A and CRTAC1-B two subtypes according to the last exon. Previous study found that inhibition of CRTAC1 reduces ultraviolet B irradiation induced-apoptosis through P38 mitogen-activated protein kinase and jun Amino-Terminal kinase pathway ([@ref-12]). It means that the relationship between the expression of CRTAC1 and apoptosis is positively correlated after ultraviolet B irradiation. To some extent, this is consistent with our finding that CRTAC1 high expression prolongs survival time in LGG patients. However, its detailed mechanism in LGG remains to be further explored. Semaphorins are a large family of conserved secreted and membrane associated proteins which possess a semaphoring (Sema) domain and a PSI domain in the N-terminal extracellular portion. Based on sequence and structural similarities, semaphorins are put into eight classes: invertebrates contain classes 1 and 2, viruses have class 8, and vertebrates contain class 3--7. Semaphorins serves as axon guidance ligands via multimeric receptor complexs, some containing plexin proteins. Semaphorins and Plexins are cognate ligand-receptor families that regulate important steps during nervous system development ([@ref-17]). A low-expression of SEMA4G was detected in colorectal cancer tissues compared with normal tissues. It means that SEMA4G might be a tumor suppressor gene related to colorectal cancer ([@ref-25]). However, little work has been done to elucidate the role of SEMA4G in glioma. Our study demonstrated that SEMA4G was significantly down-regulated in grade III patients compared to grade II and the high-expression of SEMA4G was associated with a good prognosis in LGG patients. Further work is needed to explore its functions in LGG. To sum up, the three-gene signature could predict LGG survival based on a risk score model. We firmly believed that these genes are potential prognostic markers or therapeutic targets for LGG patients. Nevertheless, the molecular mechanisms how the three-gene signature affected the prognosis of LGG patients should be further elucidated by a series of experiments.

Conclusion
==========

In conclusion, our study identified a 3-gene model that showed satisfactory performance in predicting short- and long-term survival of LGG patients compared to other models. Moreover, our finding provided new insights into the pathogenesis and prognosis of LGG.
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###### Weighted gene co-expression network of LGG.

(A-B) Identification of the soft threshlold according to the standard of the scale-free network. (C) Identification of a co-expression module in LGG. The branches of the cluster dendrogram correspond to the 17 different gene modules. Each piece of the leaves on the cluster dendrogram corresponds to a gene. (D) Correlation between the gene module and clinical traits (vital status). The correlation coefficient in each cell represented the correlation between the gene module and the clinical traits (vital status), which decreased in size from red to blue. The corresponding P value is annotated.
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###### The Gene Ontology analysis of genes in the specify modules.

\(E\) The Gene Ontology analysis results of module green containing WEE1. (F) The Gene Ontology analysis results of module yellow containing CRTAC1.
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###### The Gene Ontology analysis of genes in the specify modules.

\(G\) The Gene Ontology analysis results of module black containing SEMA4G.

###### 

Click here for additional data file.
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###### Expression information of training set.

###### 

Click here for additional data file.

10.7717/peerj.8312/supp-8

###### Validation code.

###### 

Click here for additional data file.
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###### Clinical information of training set.

###### 

Click here for additional data file.
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